THE UC SANTA CRUZ Genomics Institute received a $2.5 million, five-year grant from the St. Baldrick's Foundation, in support of the institute's Treehouse Childhood Cancer Initiative.
At a June 21 joint meeting, the NCI Board of Scientific Advisors and the National Cancer Advisory Board approved three concepts and deferred one:
MD Anderson surveyed 450 faculty, trainees and staff Sept. 29 through Nov. 10, 2015, to gather their opinions on campus-carry gun laws. Here's what they said:
In response to Texas concealed carry laws, MD Anderson proposed a plan that would allow guns only in designated buildings—the rest, specifically areas of worship and hospital facilities, are gun-exclusion zones.
This may not be the sort of targeted therapy Texas healthcare institutions wish to be known for, but starting Aug. 1, visitors to designated areas at MD Anderson Cancer Center, UT Southwestern, and UT Health Science Center at San Antonio will be able to carry their guns.
NCI is developing an open-source application intended to make it easier for patients and physicians to get information on clinical trials supported by the institute.
Vice President Joe Biden announced a new NCI application programming interface June 29 that will enable third-party developers to connect their bioinformatics software to NCI's clinical trials database.
Eli Lilly and Company and Boehringer Ingelheim will collaborate on a phase Ib study that will evaluate the safety and tolerability of Lilly’s abemaciclib in combination with Boehringer Ingelheim’s BI 836845, in patients with HR+, HER2- metastatic breast cancer. According to the companies, the collaboration has the potential to expand to phase II trials in... […]
Guardant Health and OncoMed Pharmaceuticals will collaborate using Guardant Health’s digital sequencing technology to develop a custom blood test that looks for specific biomarkers relevant to OncoMed’s ongoing phase Ia/Ib trial of its anti-RSP03 antibody. RSPO3 gene overexpression, including RSPO3 gene fusions, appear to drive tumor growth in subsets of several cancers, including colon, ovarian,... […]
The U.K.’s National Institute for Health and Care Excellence recommended the use of Firmagon (degarelix) for men with advanced hormone-dependent prostate cancer with spinal metastases. This announcement follows a three-year review process and NICE’s most recent draft Appraisal Consultation Document published in June 2015, which recommended against the use of Firmagon within its marketing authorization... […]
